Verve Therapeutics is a clinical-stage biotech developing single-course gene editing medicines for atherosclerotic cardiovascular disease (ASCVD). Rather than replacing daily pills or frequent injections, Verve aims to permanently silence disease-causing genes in the liver with a single intravenous infusion, designed to produce a lifelong therapeutic effect. The core mechanism uses base editing — delivered via lipid nanoparticles — to make a precise, permanent single-letter DNA change in liver cells, turning off genes that drive high cholesterol and related lipid levels. Verve's three programs target the main lipoprotein pathways driving ASCVD: PCSK9 (VERVE-102, in Phase 1b), ANGPTL3 (VERVE-201, in Phase 1b), and Lp(a) (VERVE-301, preclinical). Initial target patients are those with familial hypercholesterolemia or refractory hypercholesterolemia who remain at high risk despite existing therapies. Eli Lilly holds opt-in rights to co-develop and co-commercialize the PCSK9 and ANGPTL3 programs, and funds the Lp(a) program under an exclusive research collaboration. Verve has no approved products and funds operations through equity raises and the Lilly partnership. If products reach market, Verve's one-time treatment model creates pricing leverage — a durable cure can command a premium over a lifetime of chronic medication — but also introduces reimbursement complexity around high upfront treatment costs.